Home > Protocol Summaries: Compounds > GW590735 Protocol Summaries: GW590735 GSKStudy ID Phase Title Status PAA20001 phase 2 A multi-center, three-staged, randomized, parallel group, sequential, double-blind, fenofibrate-and placebo-controlled dose-response evaluation of the safety, tolerability, and effects on plasma HDLc and TG of eight weeks treatment with 1µg to 20µg daily doses of GW590735 in otherwise healthy subjects with low HDLc, mildly to moderately elevated TG, and normal LDLc Completed
